Harm reduction and quitting techniques used by heavy MDMA (ecstasy) users

References

• Alexander BK. 2008. The globalisation of addiction: a study in poverty of the spirit. Oxford: Oxford University Press.
   Google Scholar
• Allott K, Redman J. 2006. Patterns of use and harm reduction practices of ecstasy users in Australia. Drug Alcohol Depend. 82(2):168–176.
   PubMed Web of Science ®Google Scholar
• Aronson J. 2015. Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 16th ed. Oxford: Elsevier.
   Google Scholar
• Barceloux D. 2012. Medical toxicology of drug abuse: synthetized chemicals and psychoactive plants. Med Toxicol Drug Abuse. 788–804.
   Google Scholar
• Braun V, Clarke V. 2006. Using thematic analysis in psychology. Qual Res Psychol. 3(2):77–101.
   Google Scholar
• Buckley, NA. 2012. Methylenedioxymethamphetamine (Ecstasy, MDMA). In: Barceloux D, editor. Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants Hoboken: John Wiley & Sons; p. 126–155.
   Google Scholar
• Capela JP, Bastos ML, Carvalho F. 2014. Ecstasy. In: Aminoff MJ, Daroff RB, editors. Encyclopedia of the neurological sciences. London: Elsevier; p. 1064–1067.
   Google Scholar
• Curran HV, Travill R. A. 1997. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, ’ecstasy’): week-end “high” followed by mid-week low. Addiction. 92(7):821–831.
   PubMed Web of Science ®Google Scholar
• Dalgarno P, Shewan D. 2005. Reducing the risks of drug use: the case for set and setting. Addict Res Theory. 13(3):259–265.
   Web of Science ®Google Scholar
• Davison D, Parrott AC. 1997. Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol Clin Exp. 12(3):221–226.
   Web of Science ®Google Scholar
• Davis AK, Rosenberg H. 2014. The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users. J Psychoactive Drugs. 46(2):154–161.
   PubMed Web of Science ®Google Scholar
• Davis AK, Rosenberg H. 2015. Application of the passionate attachment model to recreational use of MDMA/ecstasy. J Psychoactive Drugs. 47(1):24–29.
   PubMed Web of Science ®Google Scholar
• Davis AK, Rosenberg H. 2016. Using the theory of planned behavior to predict implementation of harm reduction strategies among MDMA/ecstasy users. Psychol Addictive Behav. 30(4):500–508.
   PubMed Web of Science ®Google Scholar
• Davis AK, Rosenberg H. 2017. Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ecstasy users in the United States and the United Kingdom. Drug Sci Policy Law. 3:205032451771106.
   Google Scholar
• Duff C. 2008. The pleasure in context. Int J Drug Policy. 19(5):384–392.
   PubMed Web of Science ®Google Scholar
• EMCDDA. 2015. European drug report: trends and developments 2015. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.
   Google Scholar
• EMCDDA 2016. European drug report: trends and development. Retrieved from http://www.emcdda.europa.eu/system/files/publications/2637/TDAT16001ENN.pdf
   Google Scholar
• Hammersley R. 2011. Pathways through drugs and crime: desistance, trauma and resilience. J Crim Justice. 39(3):268–272.
   Web of Science ®Google Scholar
• Hammersley R, Khan F, Ditton J. 2002. Ecstasy and the rise of the chemical generation. London: Routledge.
   Google Scholar
• Hammersley R, Reid M. 2002. Why the pervasive addiction myth is still believed. Addict Res Theory. 10(1):7–30.
   Web of Science ®Google Scholar
• Hansen D, Maycock B, Lower T. 2001. Weddings, parties, anything…’, a qualitative analysis of ecstasy use in Perth, Western Australia. Int J Drug Policy. 12(2):181–199.
   PubMedGoogle Scholar
• Harrison M. 1998. High society: the real voices of club culture. London: Piatkus. Retrieved from http://books.google.com/books?id=I21lAAAACAAJ&pgis=1
   Google Scholar
• Henry JA, Rella JG. 2001. Medical risks associated with MDMA use. In: Holland J, editor. Ecstasy: the complete guide: a comprehensive look at the risks and benefits of MDMA. Rochester (VT): Park Street Press; p. 71–86.
   Google Scholar
• Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller KH, Quednow BB, Liechti ME. 2014. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 9(11):1645–1652.
   PubMed Web of Science ®Google Scholar
• Jacinto C, Duterte M, Sales P, Murphy S. 2008. Maximising the highs and minimising the lows: harm reduction guidance within ecstasy distribution networks. Int J Drug Policy. 19(5):393–400.
   PubMed Web of Science ®Google Scholar
• Karlsen SN, Spigset O, Slørdal L. 2008. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Basic Clin Pharmacol Toxicol. 102:15–24.
   PubMed Web of Science ®Google Scholar
• Krolikowski AM, Koyfman A. 2014. Methamphetamine and MDMA: ‘Safe’ drugs of abuse. Afr J Emerg Med. 4(1):34–38.
   Google Scholar
• Lee JP, Battle RS, Soller B, Brandes N. 2011. Thizzin’ – ecstasy use contexts and emergent social meanings. Addict Res Theory. 19(6):528–541.
   PubMed Web of Science ®Google Scholar
• Malins P. 2004. Machinic assemblages: Deleuze, Guattari and an ethico-aesthetics of drug use. Janus Head. 7(1):84–104.
   Google Scholar
• McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. 1998. Positron emission tomographic evidence of toxic effect of MDMA (‘Ecstasy’) on brain serotonin neurons in human beings. Lancet. 352(9138):1433–1437.
   PubMed Web of Science ®Google Scholar
• McGuire P. 2000. Long term psychiatric and cognitive effects of MDMA use. Toxicol Lett. 112–113:153–156.
   PubMed Web of Science ®Google Scholar
• Montag C, Becker B. 2016. Chapter 44 – recreational use of ecstasy (MDMA) and hippocampal memory: a focus on imaging. In: Preedy V, editor. Neuropathology of drug addictions and substance misuse. London: Elsevier; p. 473–483.
   Google Scholar
• Müller CP, Schumann G. 2011. Drugs as instruments: a new framework for non-addictive psychoactive drug use. Behav Brain Sci. 34(6):293–310.
   PubMed Web of Science ®Google Scholar
• Murray JB. 2001. Ecstasy is a dangerous drug. Psychol Rep. 88(3):895–902.
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Ricciardelli L. A. 2005. Harm reduction and decision making among recreational ecstasy users. Int J Drug Policy. 16(1):54–64.
   Web of Science ®Google Scholar
• Parrott AC. 2004. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology. 173(3-4):234–241.
   PubMed Web of Science ®Google Scholar
• Parrott AC, Lock J, Conner AC, Kissling C, Thome J. 2008. Dance clubbing on MDMA and during abstinence from ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology. 57(4):165–180.
   PubMed Web of Science ®Google Scholar
• Race K. 2009. Pleasure consuming medicine: the queer politics of drugs. Sydney: Duke University Press.
   Google Scholar
• Schwartz RH, Miller NS. 1997. MDMA (Ecstasy) and the rave: a review. Pediatrics. 100(4):705–708.
   PubMed Web of Science ®Google Scholar
• Sherlock K, Hay AWM, Wolff K, Conner M. 1999. Validating the consumption of Mdma (3,4-Methylenedioxymethamphetamine) in an examination of the behavioural effects of “ecstasy” amongst recreational users. Addict Res. 7(1):47–62.
   Web of Science ®Google Scholar
• ter Bogt TFM, Engels RCME. 2005. “Partying” hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse. 40(9-10):1479–1502.
   PubMed Web of Science ®Google Scholar
• Travers KR, Lyvers M. 2005. Mood and impulsivity of recreational ecstasy users in the week following a “rave. Addict Res Theory. 13(1):43–52.
   Web of Science ®Google Scholar
• Uosukainen H, Tacke U, Winstock AR. 2015. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int J Drug Policy. 26(1):78–83.
   PubMed Web of Science ®Google Scholar
• Verheyden SL, Maidment R, Curran HV. 2003. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol. 17(4):371–378. doi: http://dx.doi.org/10.1177/0269881103174014
   PubMed Web of Science ®Google Scholar
• Wu L-T, Parrott AC, Ringwalt CL, Yang C, Blazer DG. 2009. The variety of ecstasy/MDMA users: results from the national epidemiologic survey on alcohol and related conditions. Am J Addict. 18(6):452–461.
   PubMed Web of Science ®Google Scholar
• Zinberg NE. 1986. Drug, set, and setting: the basis for controlled intoxicant use. Am J Psychiatry. 143(4):548–549.
   Web of Science ®Google Scholar